4//SEC Filing
HASTINGS DAVID C 4
Accession 0001447028-24-000027
CIK 0001447028other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 7:54 PM ET
Size
9.5 KB
Accession
0001447028-24-000027
Insider Transaction Report
Form 4
HASTINGS DAVID C
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-02-01+450,000→ 450,000 totalExercise: $2.40Exp: 2034-02-01→ Common Shares (450,000 underlying) - Award
Common Shares
2024-02-01+112,500→ 191,500 total - Sale
Common Shares
2024-02-02$2.31/sh−9,593$22,184→ 181,907 total
Footnotes (4)
- [F1]Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
- [F2]Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 6, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of a previous grant of restricted stock units.
- [F3]Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
- [F4]This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.
Documents
Issuer
Arbutus Biopharma Corp
CIK 0001447028
Entity typeother
Related Parties
1- filerCIK 0001237401
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 7:54 PM ET
- Size
- 9.5 KB